Melanoma Perspective

• WCM-EADO 2025 Read clinically focused news coverage of key developments from WCM-EADO 2025
  Medscape Oncology, April 03, 2025
• Who Really Needs Treatment? The Biomarker Challenge   Dr Teresa Amaral discusses considerations for avoiding treatment of patients with stage II melanoma.
  Medscape Oncology, March 27, 2025
• Refining Melanoma Treatment With Biomarker-Driven Insights   Dr. Teresa Amaral highlights the vital role of biomarkers in assessing melanoma risk and guiding personalized treatment decisions.
  Medscape Oncology, March 20, 2025
• Real-World Data Shows Promise for Advanced Melanoma Patients Dr. Maurie Markman explores real-world data on long-term survival rates for patients with advanced melanoma, highlighting promising treatment outcomes.
  Medscape Oncology, March 12, 2025
• Should We Be Concerned About These BP Medicines? Assess risk factors and advise patients before prescribing thiazides and ACE inhibitors for blood pressure management.
  Medscape Internal Medicine, February 28, 2025
• Understanding Biomarkers in Early-Stage Melanoma   Dr Teresa Amaral explores the role of ideal biomarkers in early-stage melanoma, using an example case to highlight key considerations.
  Medscape Oncology, February 24, 2025
• Skills Lab: Clinical Trial Methods — Focus on the Control Arm   Dr Bishal Gyawali discusses the methods section of clinical trial publications, focusing on potential issues with the control arm.
  Medscape Oncology, January 22, 2025
• Vulvar and Vaginal Melanoma: A Rare but Important Diagnosis Katherine Tucker, MD, discusses the rarity of vaginal melanoma and the importance of raising awareness to improve early detection and treatment outcomes.
  Medscape Ob/Gyn, January 10, 2025
• Continuing Melanoma Research: Why, How, What?   Dr Teresa Amaral discusses why it is important to continue speaking about melanoma.
  Medscape Oncology, January 06, 2025
• Drug Combinations Improve Survival in Melanoma Dr Jeffrey Weber discusses oral melanoma abstracts presented at ASCO 2024.
  Medscape Oncology, July 25, 2024
• Phototherapy for Psoriasis: When Is It the Right Choice?   Drs Tina Bhutani, Mona Shahriari, and Jason Hawkes discuss the use of phototherapy in the treatment of psoriasis as they work toward optimal outcomes in patient care.
  Medscape Dermatology, July 16, 2024
• Unlocking ASCO 2024: Must-Know Breakthroughs   Unlocking ASCO 2024: Discover breakthrough insights from the ESOPEC, CROWN, and NADINA trials. Elevate your practice with cutting-edge knowledge. Join us for expert analysis and discussion!
  Medscape Oncology, July 11, 2024
• Phantom Cell Lines Undermine Cancer Research Credibility Research containing mistakes (or academic malfeasance) has been included in literature reviews, sowing confusion and uncertainty.
  Medscape Oncology, June 18, 2024
• ACMS 2024 Read clinically focused news coverage of key developments from ACMS 2024
  Medscape Dermatology, May 03, 2024
• ESMO Recap: Adjuvant Vs. Neoadjuvant Therapy in Melanoma Dr Jeffrey Weber discusses adjuvant and neoadjuvant therapy in melanoma.
  Medscape Oncology, April 25, 2024
• ESMO : Breakthroughs in Melanoma Treatment Regimens   Dr Jeffrey Weber discusses recent abstracts focused on melanoma, as presented at ESMO.
  Medscape Oncology, April 18, 2024
• Weighing the Balance: Immunotherapy for Cancer Treatment   Prof David Kerr discusses immunotherapy for the treatment of cancer and the importance of considering the risks and benefits of treatment.
  Medscape Oncology, April 12, 2024
• Science Fiction Becomes Fact: Neoantigen Therapy in Melanoma   Prof David Kerr discusses neoantigen therapy for patients with melanoma.
  April 05, 2024
• Adjuvant IO: Survival Advantage 'Big News' in Renal Cancer   A 40% reduced risk for death from renal cancer, as reported by KEYNOTE-564, tops Dr Brian Rini's list of takeaways from ASCO GU 2024. Also discussed are updates on doublet therapy in advanced disease.
  Medscape, March 12, 2024
• Unleashing Our Immune Response to Quash Cancer We need to ramp up our game if we are going to be able to use our immune system to quash a cancer. Fortunately, we have abundant and ever-growing capabilities for doing just that.
  Medscape, February 20, 2024